Runway Growth Finance Corp. Closes Acquisition of SWK Holdings Corporation and Provides Q1 2026 Update
Runway Growth Finance Corp. Finalizes \$249 Million Acquisition of SWK Holdings Corporation, Expands Healthcare Exposure
Key Highlights
- Acquisition of SWK Holdings Corporation completed on April 6, 2026.
- Total transaction value: \$249 million (comprising \$75.5 million in Runway Growth shares at \$11.93 NAV/share and \$173.5 million in cash).
- Runway Growth Capital LLC, as external adviser, contributed an additional \$9 million in cash to SWK shareholders, separate from the main consideration.
- The acquisition expands Runway Growth’s balance sheet to \$1.2 billion in total assets (pro forma).
- Significant increase in healthcare and life sciences portfolio exposure: from 14% to approximately 32% of total investments.
- Transaction expected to be accretive to net investment income, enhancing earnings power and supporting future dividend coverage.
- First quarter of 2026: \$17.6 million in new and follow-on investments funded.
- Significant liquidity events: \$19 million in repayments and asset sales realized during the quarter.
- Leadership update: CEO and Founder David Spreng returns as Chief Investment Officer; Investment Committee now includes Spreng, Tom Raterman, and Patrick Schafer.
Detailed Analysis for Investors
Runway Growth Finance Corp. (Nasdaq: RWAY) has completed its high-profile acquisition of SWK Holdings Corporation, a specialist in providing minimally dilutive financing to small- and mid-sized commercial-stage healthcare companies. The final deal closed on April 6, 2026, at a value of \$249 million, funded by a combination of newly issued shares and cash.
Notably, Runway Growth’s external adviser, Runway Growth Capital LLC, contributed an extra \$9 million in cash, demonstrating strong internal confidence in the combined entity’s prospects and alignment with BDC shareholders’ interests.
This acquisition is a transformative event for Runway Growth, immediately boosting its asset base to \$1.2 billion and nearly doubling its healthcare and life sciences portfolio allocation. This strategic move accelerates the company’s diversification into a sector recognized for resilience and growth potential, which may be viewed favorably by investors seeking exposure to healthcare and life sciences.
Management expects the deal to be accretive to net investment income, which is critical for dividend coverage and long-term shareholder returns. This should be closely monitored by investors, as any improvement in earnings power could support future dividend increases or stability, both significant share price drivers.
Q1 2026 Business and Portfolio Update
New and Follow-On Investments
-
Four investments totaling \$17.6 million funded in Q1 2026:
- HR Pharmaceuticals Inc. (HR Healthcare): \$7.5 million total, with \$5.5 million in debt and \$2 million in preferred equity. HR Healthcare is a founder-owned medical products platform targeting acute and home care markets.
- Follow-on investments: \$10.1 million across three existing portfolio companies.
- Dossier (13 Scents Inc.): Additional \$46.3 million debt commitment (to be partially funded in Q2 2026). Dossier is a digitally-native fragrance brand expanding its product offerings.
Liquidity Events
- Moximed, Inc.: Full repayment of \$15 million senior secured term loan.
- Shepard Intermediate (Federal Hearings and Appeals Services): Partial principal repayment of \$0.3 million.
- Other scheduled loan amortizations: \$1.7 million.
- Pivot3 Inc. asset sales: \$2.0 million in proceeds.
These liquidity events collectively returned \$19 million to Runway Growth, which may enhance flexibility for future investments or shareholder returns.
Portfolio Construction and Management
As of March 31, 2026, Runway Growth’s portfolio consisted of 44 debt investments in 32 companies and 71 equity investments in 47 companies (with 23 companies holding both debt and equity stakes). The company maintains a credit-first approach, focusing on high-quality, late-stage companies in healthcare, technology, and select consumer sectors. This disciplined underwriting and proactive portfolio monitoring are core pillars supporting the company’s reputation as a preferred lender in the venture debt market.
Leadership and Investment Team Changes
CEO and Founder David Spreng has reclaimed the role of Chief Investment Officer, effective immediately. The Investment Committee now comprises David Spreng, CFO/COO Tom Raterman, and Patrick Schafer (Partner, BC Partners Credit). This move signals a renewed focus on investment decision-making at the highest level.
Shareholder Considerations and Price-Sensitive Information
-
The SWK acquisition is a major development, expected to be accretive to net investment income and to support future dividends—factors that are typically favorable for share price appreciation.
-
The significant expansion in healthcare and life sciences exposure positions Runway Growth for further growth and diversification, reducing sector concentration risk.
-
The \$9 million cash contribution from Runway Growth Capital LLC demonstrates strong confidence from management and alignment with shareholders, which may reassure the market and support share values.
-
Leadership changes, particularly the return of David Spreng as CIO, could be viewed as a positive for investment strategy execution.
Advisors
- Legal counsel to Runway Growth: Simpson Thacher & Bartlett LLP
- SWK’s financial advisor: Keefe, Bruyette & Woods, A Stifel Company
- SWK’s legal counsel: Goodwin Procter LLP
About Runway Growth Finance Corp.
Runway Growth is a specialty finance company focused on providing flexible capital solutions to late- and growth-stage companies, operating as a closed-end investment fund regulated as a business development company. Externally managed by Runway Growth Capital LLC (an affiliate of BC Partners Advisors L.P.) and led by David Spreng, the company has built a reputation for disciplined credit investing in high-growth sectors.
Contact Information
Disclaimer: This article is for informational purposes only and does not constitute investment advice or an offer to sell or a solicitation of an offer to buy any securities. Investors should review all relevant filings and disclosures, including risk factors described in the company’s SEC filings, before making any investment decisions. Forward-looking statements are subject to risks and uncertainties and actual results may differ materially from those projected.
View Runway Growth Finance Corp. Historical chart here
